N-hydroxy-2-methyl-2-(methylsulfonyl)-4-{4-[3-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl}butanamide;

4-{4-[1-(4-fluorophenyl)-1H-imidazol-4-yl]-1H-pyrazol-1-yl}-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

N-hydroxy-2-methyl-2-(methylsulfonyl)-4-{4-[4-(1,2,3-thiadiazol-4-yl)phenyl]-1H-pyrazol-1-yl}butanamide;

4-[4-(2-ethyl-1,3-benzothiazol-6-yl)-1H-pyrazol-1-yl]-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

N-hydroxy-2-methyl-4-{4-[4-(2-methylpyrimidin-4-yl)phenyl]-1H-pyrazol-1-yl}-2-(methylsulfonyl)butanamide;

or a pharmaceutically acceptable salt thereof.

24. The compound according to claim 1 wherein

X is CR^4; and

Y is N.

25. The compound according to claim 24 wherein

R^1 is methyl;

R^2 is methyl;

R^3 is hydrogen;

R^4 is hydrogen;

L is a bond;

R^7 is $(C_6\text{-}C_{12})$aryl; and

R^8 is absent.

26. The compound according to claim 24 that is N-hydroxy-2-methyl-2-(methylsulfonyl)-4-(4-phenyl-1H-imidazol-1-yl)butanamide or a pharmaceutically acceptable salt thereof.

27. A pharmaceutical compostion comprising a compound according to any of claims 1-26 in admixture with at least one pharmaceutically acceptable excipient.

28. A method for treating bacterial infections comprising administering a therapeutically effect amount of a compound according to any of claims 1-26 to a patient in need thereof.

29. Use of a compound according to any of claims 1-26 in the manufacture of a medicament for bacterial infections.

N-hydroxy-2-methyl-2-(methylsulfonyl)-4-{4-[3-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl}butanamide;

4-{4-[1-(4-fluorophenyl)-1H-imidazol-4-yl]-1H-pyrazol-1-yl}-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

N-hydroxy-2-methyl-2-(methylsulfonyl)-4-{4-[4-(1,2,3-thiadiazol-4-yl)phenyl]-1H-pyrazol-1-yl}butanamide;

4-[4-(2-ethyl-1,3-benzothiazol-6-yl)-1H-pyrazol-1-yl]-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

N-hydroxy-2-methyl-4-{4-[4-(2-methylpyrimidin-4-yl)phenyl]-1H-pyrazol-1-yl}-2-(methylsulfonyl)butanamide;

or a pharmaceutically acceptable salt thereof.

24. The compound according to claim 1 wherein

X is CR^4; and

Y is N.

25. The compound according to claim 24 wherein

R^1 is methyl;

R^2 is methyl;

R^3 is hydrogen;

R^4 is hydrogen;

L is a bond;

R^7 is $(C_6\text{-}C_{12})$aryl; and

R^8 is absent.

26. The compound according to claim 24 that is N-hydroxy-2-methyl-2-(methylsulfonyl)-4-(4-phenyl-1H-imidazol-1-yl)butanamide or a pharmaceutically acceptable salt thereof.

27. A pharmaceutical compostion comprising a compound according to any of claims 1-26 in admixture with at least one pharmaceutically acceptable excipient.

28. Use of a compound according to any of claims 1-26 in the manufacture of a medicament for bacterial infections.